113. 筋ジストロフィー
[臨床試験数:567,薬物数:442(DrugBank:93),標的遺伝子数:55,標的パスウェイ数:151

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-003195-68-GB
(EUCTR)
11/11/201526/10/2015Testosterone therapy in DMDObservational study of clinical outcomes for testosterone treatment of pubertal delay in Duchenne Muscular Dystrophy. - Testosterone therapy in Duchenne Muscular Dystrophy Duchenne Muscular Dystrophy
MedDRA version: 18.1;Level: PT;Classification code 10013801;Term: Duchenne muscular dystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Sustanon 250
Product Name: Sustanon 250
Product Code: PRD2175434
INN or Proposed INN: testosterone propionate
INN or Proposed INN: testosterone phenylpropionate
INN or Proposed INN: testosterone isocaproate
INN or Proposed INN: testosterone decanoate
The Newcastle upon Tyne NHS Hospitals Foundation TrustNULLNot RecruitingFemale: no
Male: yes
20Phase 3United Kingdom